Literature DB >> 16822880

Low meprin alpha expression differentiates primary ovarian mucinous carcinoma from gastrointestinal cancers that commonly metastasise to the ovaries.

Viola A Heinzelmann-Schwarz1, Richard A Scolyer, James P Scurry, Alison N Smith, Margaret Gardiner-Garden, Andrew V Biankin, Sally Baron-Hay, Carolyn Scott, Robyn L Ward, Daniel Fink, Neville F Hacker, Robert L Sutherland, Philippa M O'Brien.   

Abstract

BACKGROUND: Currently, no specific immunohistochemical markers are available to differentiate primary mucinous epithelial ovarian cancer (MOC) from adenocarcinomas originating at other sites that have metastasised to the ovary, which may have an impact on patient management and prognosis. AIM: To investigate the expression of two intestinal markers, galectin 4 and meprin alpha, in mucinous carcinomas of the ovary and gastrointestinal tract.
METHODS: Using immunohistochemical analysis, the expression of galectin 4 and meprin alpha was investigated in 10 MOCs and in 38 mucinous adenocarcinomas of colon, pancreas, stomach and appendix, the most common sites of origin of ovarian metastases.
RESULTS: Total cytoplasmic galectin 4 expression was relatively consistent between the different carcinomas. Membranous meprin alpha expression was significantly lower in MOCs compared with gastrointestinal carcinomas. Moreover, meprin alpha expression showed greater discrimination between the ovarian and gastrointestinal carcinomas than the cytokeratins CK7 and CK20, the current standard immunohistochemical markers used to determine the tissue origin of mucinous carcinomas involving the ovaries.
CONCLUSIONS: Meprin alpha is a useful additional marker in differentiating primary from secondary mucinous adenocarcinomas of the ovary.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16822880      PMCID: PMC1955076          DOI: 10.1136/jcp.2005.034223

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  27 in total

1.  Cloning and expression of the mRNA of human galectin-4, an S-type lectin down-regulated in colorectal cancer.

Authors:  H Rechreche; G V Mallo; G Montalto; J C Dagorn; J L Iovanna
Journal:  Eur J Biochem       Date:  1997-08-15

2.  Evaluation of diagnostic criteria and behavior of ovarian intestinal-type mucinous tumors: atypical proliferative (borderline) tumors and intraepithelial, microinvasive, invasive, and metastatic carcinomas.

Authors:  M A Riopel; B M Ronnett; R J Kurman
Journal:  Am J Surg Pathol       Date:  1999-06       Impact factor: 6.394

3.  Nonpolarized secretion of human meprin alpha in colorectal cancer generates an increased proteolytic potential in the stroma.

Authors:  D Lottaz; C A Maurer; D Hahn; M W Büchler; E E Sterchi
Journal:  Cancer Res       Date:  1999-03-01       Impact factor: 12.701

4.  Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma.

Authors:  Sanjay Logani; Esther Oliva; Paula M Arnell; Mahul B Amin; Robert H Young
Journal:  Mod Pathol       Date:  2005-01       Impact factor: 7.842

5.  The value of Cdx2 immunostaining in differentiating primary ovarian carcinomas from colonic carcinomas metastatic to the ovaries.

Authors:  Gabriel M Groisman; Alona Meir; Edmond Sabo
Journal:  Int J Gynecol Pathol       Date:  2004-01       Impact factor: 2.762

6.  The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin.

Authors:  Jeffrey D Seidman; Iren Horkayne-Szakaly; Moutaz Haiba; Charles R Boice; Robert J Kurman; Brigitte M Ronnett
Journal:  Int J Gynecol Pathol       Date:  2004-01       Impact factor: 2.762

Review 7.  Galectin-4 in normal tissues and cancer.

Authors:  Margaret E Huflejt; Hakon Leffler
Journal:  Glycoconj J       Date:  2004       Impact factor: 2.916

8.  The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas.

Authors:  Vassil Kaimaktchiev; Luigi Terracciano; Luigi Tornillo; Hanspeter Spichtin; Dimitra Stoios; Marcel Bundi; Veselina Korcheva; Martina Mirlacher; Massimo Loda; Guido Sauter; Christopher L Corless
Journal:  Mod Pathol       Date:  2004-11       Impact factor: 7.842

9.  A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas.

Authors:  S Detre; G Saclani Jotti; M Dowsett
Journal:  J Clin Pathol       Date:  1995-09       Impact factor: 3.411

10.  CDX-2 immunostaining in primary and secondary ovarian carcinomas.

Authors:  L Tornillo; H Moch; P-A Diener; A Lugli; G Singer
Journal:  J Clin Pathol       Date:  2004-06       Impact factor: 3.411

View more
  7 in total

1.  Serum antiglycan antibody detection of nonmucinous ovarian cancers by using a printed glycan array.

Authors:  Francis Jacob; Darlene R Goldstein; Nicolai V Bovin; Tatiana Pochechueva; Marianne Spengler; Rosemarie Caduff; Daniel Fink; Marko I Vuskovic; Margaret E Huflejt; Viola Heinzelmann-Schwarz
Journal:  Int J Cancer       Date:  2011-04-25       Impact factor: 7.396

Review 2.  Meprin A metalloproteinase and its role in acute kidney injury.

Authors:  Gur P Kaushal; Randy S Haun; Christian Herzog; Sudhir V Shah
Journal:  Am J Physiol Renal Physiol       Date:  2013-02-20

3.  Galectin-4 Reduces Migration and Metastasis Formation of Pancreatic Cancer Cells.

Authors:  Ana I Belo; Astrid M van der Sar; Boris Tefsen; Irma van Die
Journal:  PLoS One       Date:  2013-06-18       Impact factor: 3.240

Review 4.  The metalloproteases meprin α and meprin β: unique enzymes in inflammation, neurodegeneration, cancer and fibrosis.

Authors:  Claudia Broder; Christoph Becker-Pauly
Journal:  Biochem J       Date:  2013-03-01       Impact factor: 3.857

5.  Assessment of galectins -1, -3, -4, -8, and -9 expression in ovarian carcinoma patients with clinical implications.

Authors:  Radwa Mansour Mohamed; Athar Emam; Mahmoud M Abdelfattah; Abdel-Mageed Ismail Abdel-Mageed; Mohamed A Abdelhafeez; Reham Helwa
Journal:  World J Surg Oncol       Date:  2022-09-01       Impact factor: 3.253

6.  Urinary signatures of Renal Cell Carcinoma investigated by peptidomic approaches.

Authors:  Clizia Chinello; Marta Cazzaniga; Gabriele De Sio; Andrew James Smith; Erica Gianazza; Angelica Grasso; Francesco Rocco; Stefano Signorini; Marco Grasso; Silvano Bosari; Italo Zoppis; Mohammed Dakna; Yuri E M van der Burgt; Giancarlo Mauri; Fulvio Magni
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

7.  Predictive value of MEP1A in cancer prognosis: A protocol for systematic review and meta-analysis.

Authors:  Yong Chen; Fangfang Wu; Li Zhang; Li Du; Xiang Yan
Journal:  Medicine (Baltimore)       Date:  2020-11-06       Impact factor: 1.817

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.